Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Status:
Completed
Trial end date:
2019-10-23
Target enrollment:
Participant gender:
Summary
This is an open-label extension study intended to provide continued treatment with migalastat
hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous
migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat
HCl.